Reduced-Toxicity Conditioning With Fludarabine, Once-Daily Intravenous Busulfan, and Antithymocyte Globulins Prior to Allogeneic Stem Cell Transplantation: Results of a Multicenter Prospective Phase 2 Trial

摘要

BACKGROUNDThe optimal intensity of myeloablation delivered as part of a reduced-intensity/toxicity conditioning (RIC/RTC) regimen to decrease the recurrence rate, without increasing nonrecurrence mortality (NRM), remains to be established.